Mexican beaded lizard Mexican beaded lizard The Mexican beaded lizard ("Heloderma horridum") is a species of lizard in the family Helodermatidae, one of the two species of venomous beaded lizards found principally in Mexico and southern Guatemala. It and its congener (member of the same genus) the Gila monster ("Heloderma suspectum") are the only lizards known to have evolved an overt venom delivery system. The Mexican beaded lizard is larger than the Gila monster, with duller coloration, black with yellowish bands. As it is a specialized predator that feeds primarily upon eggs, the primary use of its venom is still a source of
Mexican beaded lizard (swelling), weakness, sweating, and a rapid fall in blood pressure. Beaded lizards are immune to the effects of their own venom. Some compounds in its venom have been shown to have pharmacological properties relating to the possible treatment of diabetes, Alzheimer's disease, and even HIV. One compound, a hormone named exendin-3, is marketed by Amylin Pharmaceuticals as the drug exenatide. A study in 1996 revealed that it binds to cell receptors in breast cancer cells and may stop the growth of lung cancer cells. The beaded lizard becomes sexually mature at six to eight years and mates between September and